Market – Page 4 – Talk Bio

Actionable Insights Powered by AI

Biotech M&A Heats Up: Cosette’s $430M Mayne Pharma Acquisition and Industry-Wide Stock Buybacks

4 months ago talkbio0Tagged Acquisitions, biotech, Dermatology field, Lung consolidation, Market, pharmaceutical mergers, stock repurchase programs, women 's health

Biotech acquisitions, pharmaceutical mergers, stock repurchase programs, women’s health, dermatology, market consolidation

Biotech IPO Momentum: Maze and Metsera’s Dual Debut Signals Renewed Market Optimism

4 months ago talkbio0Tagged amsacrine/azacitidine/etoposide, biotech, IPO, IPOs, Market, Metsera, Obesity, Optimism, Precision Medicine, trends qualifier

Biotech IPOs, Maze Therapeutics, Metsera, obesity treatment, precision medicine, market optimism, 2025 IPO trends

Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

4 months ago talkbio0Tagged Antibodies, Beyfortus, blockbuster sales, Growth, Infant, Market, Protection, Respiratory syncytial virus, sanofi, U.S.

Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

4 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings

5 months ago talkbio0Tagged 2025, File (record), Health care facility, Industry, IPO, JPM, Market, Odyssey, Sionna

Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market

Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge

5 months ago talkbio0Tagged Alzheimer 's disease, Biogen, Donanemab, Eisai, Eli, Eli Lilly, Growth, Kisunla, Leqembi, Market

Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

5 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

Tenpoint Therapeutics Prepares for 2026 Market Launch Following Successful Phase 3 Trial of BRIMOCHOL PF for Presbyopia Treatment

5 months ago talkbio0Tagged BRIMOCHOL, fluorouracil/melphalan, launch, Market, Phase 3 trial, presbyopia, Tenpoint Therapeutics

Tenpoint Therapeutics, BRIMOCHOL PF, Presbyopia treatment, Phase 3 trial, Combination eye drop, 2026 market launch

FDA Sets Efficacy Threshold for Obesity Therapies Amid Market Expansion

5 months ago talkbio0Tagged Effectiveness, Market, Obesity, standards characteristics, trends qualifier, United States Food and Drug Administration, Weight-Loss

FDA, obesity therapies, weight-loss treatments, efficacy standards, obesity market trends

Q32 Bio Inc. Faces Market Volatility After Bempikibart Program Update

6 months ago talkbio0Tagged Autoimmune Diseases, bempikibart, Bio Inc., IL-7/TSLP pathways, Market, Performance, Volatility

Q32 Bio Inc., bempikibart, autoimmune diseases, IL-7/TSLP pathways, stock performance, market volatility